IP Library Patent Application 16448588
Patent Application
App. No. 16/448,588

INTRAOCULAR DELIVERY OF BIOACTIVE MOLECULES USING IONTOPHORESIS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/448,588
Abstract

Iontophoresis, a minimally-invasive methodology that uses a weak electric current to enhance penetration of ionized molecules into tissues, was found to be an effective technique for the intraocular delivery of large bioactive molecules, specifically lutein.

Claims (9)

1 . A method of depositing a bioactive molecule in ocular tissues, comprising the steps of formulating a liposome containing the bioactive molecule, charging an iontophoresis device with a composition of the bioactive molecule-containing liposome, applying the iontophoresis device to the eye of a subject, and operating the iontophoresis device.

2 . The method of claim 1 , wherein the bioactive molecule is selected from the group consisting of carotenoids.

3 . The method of claim 2 , wherein the carotenoid is selected from the group consisting of lutein and zeaxanthin.

4 . The method of claim 1 , wherein the liposome has a positive zeta potential.

5 . A method of treating, ameliorating or preventing an ocular disease or dysfunction, comprising the steps of formulating a liposome containing the bioactive molecule, charging an iontophoresis device with a composition of the bioactive molecule-containing liposome, applying the iontophoresis device to the eye of a subject, and operating the iontophoresis device.

6 . The method of claim 5 , wherein treating, ameliorating or preventing an ocular disease or dysfunction is delaying the onset of age-related macular degeneration.

7 . The method of claim 5 , wherein treating, ameliorating or preventing ocular disease or dysfunction is preventing or delaying the progression of age-related macular degeneration.

8 . The method of claim 5 , wherein the ocular disease or dysfunction is age-related macular degeneration.

9 . The method of claim 5 , wherein the ameliorating or preventing of an ocular disease or dysfunction comprises carrying out the method in healthy subjects.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2021
From: DE SOUSA MARTINS, DIOGO; CAVALLO, GIOVANNI; FOSCHINI, FULVIO; ROY, PIERRE
To: KEMIN INDUSTRIES, INC.
Reel/Frame 056846/0972 →
GRANT OF PATENT SECURITY INTEREST Recorded Jul 12, 2021
From: KEMIN INDUSTRIES, INC.; KEMIN HOLDINGS, L.C.; KEMIN FOODS, L.C.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 056832/0569 →